High resource hospitalizations among children with vaso-occlusive crises in sickle cell disease

Pediatric Blood and Cancer

Volumn 58, Issue 4, 2012, Pages 584-590

  Raphael, Jean L ^a   Mei, Minghua ^a   Mueller, Brigitta U ^a   Giordano, Thomas ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Epidemiology; Health care utilization; Outcomes research; Sickle cell disease

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; COMPARATIVE STUDY; CONSTIPATION; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; GENERAL HOSPITAL; HEALTH CARE UTILIZATION; HOSPITAL CARE; HOSPITAL COST; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; OCCLUSION; PEDIATRIC HOSPITAL; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SICKLE CELL ANEMIA; VASOOCCLUSIVE CRISIS;

ADOLESCENT; AGE FACTORS; ANEMIA, SICKLE CELL; CHILD; CHILD, PRESCHOOL; COSTS AND COST ANALYSIS; DATABASES, FACTUAL; FEMALE; HOSPITALIZATION; HOSPITALS, GENERAL; HOSPITALS, PEDIATRIC; HUMANS; INFANT; INFANT, NEWBORN; MALE; SEVERITY OF ILLNESS INDEX; VASCULAR DISEASES;

EID: 84856890836     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23181     Document Type: Article

References (45)

1. Houston-Yu P, Rana SR, Beyer B, et al. Frequent and prolonged hospitalizations: A risk factor for early mortality in sickle cell disease patients. Am J Hematol 2003; 72: 201-203.
2. Lanzkron S, Haywood C Jr, Segal JB, et al. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. Am J Hematol 2006; 81: 927-932.
3. Davis H, Moore RM Jr, Gergen PJ. Cost of hospitalizations associated with sickle cell disease in the United States. Public Health Rep 1997; 112: 40-43.
4. Moore RD, Charache S, Terrin ML, et al. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Am J Hematol 2000; 64: 26-31.
5. Kauf TL, Coates TD, Huazhi L, et al. The cost of health care for children and adults with sickle cell disease. Am J Hematol 2009; 84: 323-327.
6. Steiner CA, Miller JL. Sickle cell disease patients in U.S. hospitals; 2004. Report No.: HCUP statistical brief # 21.
7. Yang YM, Shah AK, Watson M, et al. Comparison of costs to the health sector of comprehensive and episodic health care for sickle cell disease patients. Public Health Rep 1995; 110: 80-86.
8. Nietert PJ, Abboud MR, Zoller JS, et al. Costs, charges, and reimbursements for persons with sickle cell disease. J Pediatr Hematol Oncol 1999; 21: 389-396.
9. Nietert PJ, Silverstein MD, Abboud MR. Sickle cell anaemia: Epidemiology and cost of illness. Pharmacoeconomics 2002; 20: 357-366.
10. Bilenker JH, Weller WE, Shaffer TJ, et al. The costs of children with sickle cell anemia: Preparing for managed care. J Pediatr Hematol Oncol 1998; 20: 528-533.
11. Amendah DD, Mvundura M, Kavanagh PL, et al. Sickle cell disease-related pediatric medical expenditures in the U.S. Am J Prev Med 2010; 38: S550-S556.
12. Raphael JL, Dietrich CL, Whitmire D, et al. Healthcare utilization and expenditures for low income children with sickle cell disease. Pediatr Blood Cancer 2009; 52: 263-267.
13. Mvundura M, Amendah D, Kavanagh PL, et al. Health care utilization and expenditures for privately and publicly insured children with sickle cell disease in the United States. Pediatr Blood Cancer 2009; 53: 642-646.
14. Woods K, Karrison T, Koshy M, et al. Hospital utilization patterns and costs for adult sickle cell patients in Illinois. Public Health Rep 1997; 112: 44-51.
15. Logan DE, Radcliffe J, Smith-Whitley K. Parent factors and adolescent sickle cell disease: Associations with patterns of health service use. J Pediatr Psychol 2002; 27: 475-484.
16. Raphael JL, Shetty PB, Liu H, et al. A critical assessment of transcranial doppler screening rates in a large pediatric sickle cell center: Opportunities to improve healthcare quality. Pediatr Blood Cancer 2008; 51: 647-651.
17. Yusuf HR, Atrash HK, Grosse SD, et al. Emergency department visits made by patients with sickle cell disease: A descriptive study, 1999-2007. Am J Prev Med 2010; 38: S536-S541.
18. Carroll CP, Haywood C Jr, Fagan P, et al. The course and correlates of high hospital utilization in sickle cell disease: Evidence from a large, urban Medicaid managed care organization. Am J Hematol 2009; 84: 666-670.
19. Introduction to the HCUP KIDS Inpatient Database: Agency for Healthcare Research and Quality; 2008.
20. Connor JA, Gauvreau K, Jenkins KJ. Factors associated with increased resource utilization for congenital heart disease. Pediatrics 2005; 116: 689-695.
21. Panepinto JA, Brousseau DC, Hillery CA, et al. Variation in hospitalizations and hospital length of stay in children with vaso-occlusive crises in sickle cell disease. Pediatr Blood Cancer 2005; 44: 182-186.
22. Raphael JL, Kamdar A, Beavers MB, et al. Treatment of uncomplicated vaso-occlusive crises in children with sickle cell disease in a day hospital. Pediatr Blood Cancer 2008; 51: 82-85.
23. Raphael JL, Kamdar A, Wang T, et al. Day hospital versus inpatient management of uncomplicated vaso-occlusive crises in children with sickle cell disease. Pediatr Blood Cancer 2008; 51: 398-401.
24. Ballas SK. The cost of health care for patients with sickle cell disease. Am J Hematol 2009; 84: 320-322.
25. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991; 325: 11-16.
26. Ellison AM, Bauchner H. Socioeconomic status and length of hospital stay in children with vaso-occlusive crises of sickle cell disease. J Natl Med Assoc 2007; 99: 192-196.
27. Quinn CT, Rogers ZR, McCavit TL, et al. Improved survival of children and adolescents with sickle cell disease. Blood 2010; 115: 3447-3452.
28. Treadwell M, Telfair J, Gibson RW, et al. Transition from pediatric to adult care in sickle cell disease: Establishing evidence-based practice and directions for research. Am J Hematol 2010; 86: 116-120.
29. The Management of Sickle Cell Disease: National Institutes of Health: National Heart, Lung, and Blood Institute; 2002.
30. Dove HG, Schneider KC. The usefulness of patients' individual characteristics in predicting no-shows in outpatient clinics. Med Care 1981; 19: 734-740.
31. Goldman L, Freidin R, Cook EF, et al. A multivariate approach to the prediction of no-show behavior in a primary care center. Arch Intern Med 1982; 142: 563-567.
32. Neal RD, Lawlor DA, Allgar V, et al. Missed appointments in general practice: Retrospective data analysis from four practices. Br J Gen Pract 2001; 51: 830-832.
33. Campbell B, Stanley D. Who misses appointments? An empirical analysis. Can J Psychiatry 1991; 36: 223-225.
34. Dunbar-Jacob J, Erlen JA, Schlenk EA, et al. Adherence in chronic disease. Annu Rev Nurs Res 2000; 18: 48-90.
35. Robinson N, Huber H, Jenkins Pea. Improving access to medical care for children with sickle cell disease. The 29th Annual Meeting of the National Sickle Cell Disease Program, Memphis, TN, April, 2006.
36. Crosby LE, Modi AC, Lemanek KL, et al. Perceived barriers to clinic appointments for adolescents with sickle cell disease. J Pediatr Hematol Oncol 2009; 31: 571-576.
37. Patik M, Phillips L, Kladny B, et al. Structured telephone-based outreach using nonmedical personnel can improve adherence to comprehensive care in families of children with sickle cell disease. Am J Hematol 2006; 81: 462-464.
38. Stallworth JR, Jerrell JM, Tripathi A. Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. Am J Hematol 2010; 85: 795-797.
39. Lanzkron S, Haywood C Jr, Hassell KL, et al. Provider barriers to hydroxyurea use in adults with sickle cell disease: A survey of the Sickle Cell Disease Adult Provider Network. J Natl Med Assoc 2008; 100: 968-973.
40. Haywood C Jr, Beach MC, Bediako S, et al., Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease. Am J Hematol 2010; 86: 85-87.
41. Brandow AM, Jirovec DL, Panepinto JA. Hydroxyurea in children with sickle cell disease: Practice patterns and barriers to utilization. Am J Hematol 2010; 85: 611-613.
42. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 2000; 342: 1855-1865.
43. Bellet PS, Kalinyak KA, Shukla R, et al. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N Engl J Med 1995; 333: 699-703.
44. O'Brien SH, Fan L, Kelleher KJ. Inpatient use of laxatives during opioid administration in children with sickle cell disease. Pediatr Blood Cancer 2010; 54: 559-562.
45. Shankar SM, Arbogast PG, Mitchel E, et al. Impact of proximity to comprehensive sickle cell center on utilization of healthcare services among children with sickle cell disease. Pediatr Blood Cancer 2008; 50: 66-71.